Our Studies
If you are interested in learning more information about our ongoing clinical trials, please contact us below.
ACTIVELY ENROLLING TRIALS BELOW:
- 
      
        
          
        
      
      
oral medication in patients with heart failure with preserved ejection fraction.
 - 
      
        
      
      
Self-administered subcutaneous medication for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction.
 - 
      
        
      
      
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to EvaLuate the EffIcacy and Safety of AbeLacimab in High-risk Patients with Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral AntiCoagulation
 - 
      
        
      
      
Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)
 - 
      
        
      
      
Nasal Spray for patients with A-fib
 - 
      
        
      
      
A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
 - 
      
        
      
      
SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
 - 
      
        
      
      
Oral Medication.
 - 
      
        
      
      
oral medication
 - 
      
        
      
      
Oral medication.
Mild to moderate Androgenetic Alopecia
 
Testimonials